Add Trial
Sign In

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer


Study Type Treatment
Sponsor Name Astrazeneca
Disease type Non-Small Cell Lung Cancer
Disease Stage IB – IIIA
Clinical Status Adjuvant
Phase III
Intervention / Treatment Durvalumab versus Placebo
Research Site Quebec Heart and Lung Institute
Investigator Dre Lise Tremblay
Coordinator Brigitte Fortin
Telephone number
Fax number
Study start date October 9, 2014
Study end date
Trial Status Recruiting

Listing Features


Working Hours :

Now Closed UTC - 4

Price / Claim :

Recruit a patient:

*for confidentiality, do not include the name of the patient

*pour raisons de confidentialité, n'incluez pas le nom du patient

Hosted by :

Claim listing: CCTG BR.31

Our website is under development. We're sorry for any inconvenience that might appear.Notre site web est en cours de développement. Nous sommes désolés pour tout inconvénient qui pourrait survenir.

Reply to Message


Account details will be confirmed via email.

Reset Your Password